GLP-1 and Muscle Loss: How to Protect Your Gains

GLP-1 therapy produces remarkable fat loss. But one of the most common concerns among patients - particularly active men and women - is whether that fat loss comes at the cost of hard-earned muscle.

The concern is valid. Any significant caloric deficit carries a risk of lean tissue loss alongside fat. The question is not whether GLP-1 causes muscle loss, but how to structure a program that minimises it.

Does GLP-1 Cause Muscle Loss?

GLP-1 therapy itself does not directly cause muscle breakdown. However, the caloric deficit it creates does carry muscle loss risk, as does any dietary restriction.

In the large GLP-1 clinical trials, body composition data (where measured) showed that roughly 25 to 39 percent of total weight lost was lean mass, including muscle. This is broadly consistent with natural caloric restriction without any pharmacological intervention.

The key insight: muscle loss during GLP-1 therapy is not inevitable - it is a consequence of inadequate protein intake and insufficient resistance training, not the peptide itself.

The Three Pillars of Muscle Preservation

1. High Protein Intake

Protein is the most critical variable for preserving lean mass during a caloric deficit. When caloric intake drops significantly (which it does on GLP-1), your body needs a strong protein signal to prioritise muscle retention over muscle catabolism.

The clinical recommendation for muscle preservation during active weight loss:

• 1.6 to 2.2 g of protein per kg of target body weight daily
• Distributed across three to five meals or snacks rather than concentrated in one meal
• Prioritise leucine-rich complete protein sources: eggs, chicken, fish, paneer, whey, and legume combinations

Many patients on GLP-1 therapy under-eat protein because their overall appetite is suppressed. This is a common pitfall that requires intentional management.

2. Resistance Training

Resistance training sends a direct anabolic signal to skeletal muscle: this tissue is needed and should be maintained. Without this signal, a caloric deficit will always claim some muscle alongside fat.

Practical recommendations:

• Minimum two to three full-body resistance training sessions per week
• Focus on compound movements: squats, deadlifts, rows, presses
• Progressive overload: continue challenging the muscles even as caloric intake is reduced
• Do not significantly reduce training volume or intensity during the weight loss phase

3. Peptide Stacking for Muscle Preservation

For patients with a significant muscle preservation priority (athletes, bodybuilders, or those with a history of muscle loss), Longegra may recommend adding supporting peptides to the GLP-1 protocol:

• Ipamorelin or CJC-1295: Growth hormone secretagogues that stimulate natural GH release, supporting muscle protein synthesis and fat oxidation simultaneously
• BPC-157: Supports tendon and muscle tissue repair, particularly relevant for high-training-volume patients
• IGF-1 LR3 (where appropriate): Directly stimulates muscle protein synthesis; used in specific clinical contexts under careful physician oversight

Body Composition Tracking: Knowing What Is Actually Changing

Weight on a scale tells you nothing about what you are actually losing. A loss of 10 kg that is 80 percent fat and 20 percent muscle is a dramatically better outcome than a 10 kg loss that is 60 percent fat and 40 percent muscle.

At Longegra, we recommend regular body composition assessment (via bioelectrical impedance or DEXA where accessible) alongside standard weight tracking to ensure patients are recomposing, not just losing mass indiscriminately.

Who Is Most at Risk of Muscle Loss on GLP-1?

• Patients who do not engage in any resistance training
• Those with very high rates of weight loss (more than 1.5 kg per week)
• Older adults (sarcopenia risk increases with age regardless of method)
• Patients with already low muscle mass at baseline
• Those not meeting protein targets due to appetite suppression